Study Title

PET Imaging Study of 89Zr-DFO-YS5

Study Details

Description:

CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is that CD46 expression, measured via our novel imaging biomarker, is a characteristic feature of mCRPC, and particularly common in the most lethal forms of the disease including adenocarcinoma and Small-cell neuroendocrine carcinoma (SCNC). These data will provide crucial information about the feasibility of targeting cluster of differentiation 46 (CD46) in mCRPC, will be used guide the development of novel therapeutic and theranostic agents, to help develop treatments that improve outcomes for men with the most lethal forms of prostate cancer.

Sponsor:

Fortis Therapeutics, Inc.

Contacts:

Maya Aslam

maya.aslam@ucsf.edu

877-827-3222

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468